The news: Novo Nordisk is rebranding as “Novo,” dropping a name that traces back to Nordisk Insulinlaboratorium, which began producing insulin in 1923. The Danish drugmaker's global legal name will remain Novo Nordisk.

Why it matters: Novo wants a shorter, more recognizable name that resonates with consumers.

“Novo” (Latin for “new”) aligns with the company’s broader “Novo Way” culture reset, aimed at competing in a faster-moving, consumer-driven market. Earlier this year, Novo appointed Mars CEO Poul Weihrauch as a board observer, tapping his experience tracking consumer purchasing intent, which is important in the obesity drug category where heavy advertising, extensive news coverage, celebrity endorsements, and social media content have made names such as Ozempic, Wegovy, and Zepbound widely recognizable. Novo now hopes a shorter, more distinctive corporate identity will stand out as consumers compare Novo’s weight loss drugs with Eli Lilly’s.

Novo is also signaling adaptability to investors as it seeks to regain ground against a rival increasingly branded as “Lilly.” Novo faces slower weight loss injection sales growth than Lilly, pipeline setbacks, and earlier generic competition for its GLP-1 blockbusters. Despite its GLP-1 first-mover advantage and the Wegovy pill’s early lead, these pressures have pushed its shares down about 21% over the past year, while Lilly’s have risen 53%.

The bigger picture: Shortening a brand name does not guarantee consumer recognition. People may know heavily advertised drugs such as Ozempic, Xanax, or Lipitor, but the companies behind them can remain unfamiliar. The race to develop COVID-19 vaccines briefly forced names like Pfizer and Moderna into everyday consumer vocabulary, showing that it sometimes takes historic emergencies for pharma corporate entities to register in public consciousness.

Implications for pharma brands: Dropping “Nordisk” from brand marketing won’t change the fundamentals that drive pharma success: clinical evidence, product differentiation, market access, launch execution, and sound partnership and investment decisions.

Most consumers likely won’t notice the change—they’re more likely to recognize a brand-name drug than the company behind it. And while physicians may recognize it, they’ll remain persuaded by a drug’s efficacy. Instead, the rebrand appears aimed largely at investors—especially ahead of next week’s investor day—positioning Novo as a more modern, agile company ready to move beyond its recent challenges.

The larger lesson is that a pharma rebrand must do more than refresh a name or visual identity. It should clarify the growth narrative for investors, align employees around new priorities, and show partners how the company will compete. But that story gains credibility only through tangible progress, including a more diversified pipeline, faster development and launches, and disciplined M&A decisions. Otherwise, it risks looking like a cosmetic response to deeper business pressures.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.